Cyclosporine: Nursing Drug Guide, Nephrotoxicity & Trough Monitoring
Cyclosporine prevents organ rejection and treats severe rheumatoid arthritis and psoriasis, but nursing safety hinges on nephrotoxicity surveillance, accurate trough levels, and never swapping modified (Neoral) vs non-modified (Sandimmune) products without prescriber-directed conversion. A missed formulation check or ignored creatinine trend can cause irreversible kidney injury or graft loss.
Neoral labeling warns that cyclosporine causes hypertension and nephrotoxicity that worsen with higher dose and longer therapy. Neoral (modified) and Sandimmune (non-modified) are not bioequivalent—mg-for-mg switches can cause toxicity or underdosing. Hold and clarify when serum creatinine rises, trough is supratherapeutic, or the MAR shows a product change without pharmacy verification.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every cyclosporine dose: confirm product name (modified vs non-modified), verify the latest trough and creatinine trend, screen for new nephrotoxic or CYP3A4-interacting drugs, and hold when renal markers or blood pressure cross protocol limits. Teach patients to report decreased urine output, swelling, tremor, and infection symptoms immediately.
Most common brand names
Generic: cyclosporine (ciclosporin). Product selection determines absorption—do not assume brands are interchangeable.
Common brands (systemic): Neoral (modified oral capsule/solution), Sandimmune (non-modified oral/IV), Gengraf (modified). Ophthalmic cyclosporine (e.g., Restasis) is a different topical indication—not covered by systemic Neoral dosing in this guide.
Why we give it — Indications
Per Neoral prescribing information, cyclosporine is used for transplant immunosuppression and selected autoimmune diseases when specialists manage therapy in settings with adequate laboratory support.
| Use (Neoral labeling) | Nursing relevance |
|---|---|
| Kidney, liver, and heart transplant rejection prophylaxis | Requires trough monitoring and rapid communication of rising creatinine or infection |
| Severe active rheumatoid arthritis | Used when response to methotrexate is inadequate; may combine with methotrexate |
| Severe recalcitrant plaque psoriasis | Adult nonimmunocompromised patients after failure/intolerance of systemic therapy; strict renal and BP monitoring |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Cyclosporine inhibits calcineurin, blocking interleukin-2 and other cytokines that activate T-lymphocytes. This suppresses cell-mediated immunity to prevent graft rejection and reduce autoimmune inflammation. Narrow therapeutic index means small concentration changes can tip balance between rejection and toxicity—nurses support safety through monitoring, not dose titration.
Dosing overview
Institutional transplant and autoimmune protocols vary. All cyclosporine therapy requires prescriber-directed dosing with laboratory surveillance per Neoral labeling.
Neoral and Sandimmune are not interchangeable on a mg-for-mg basis. Conversion requires increased monitoring to avoid under- or over-exposure.
Before you give it — Safety check
Pretreatment checks
- Confirm exact product on MAR: modified (Neoral/Gengraf) vs non-modified (Sandimmune) and oral vs IV route
- Review latest cyclosporine trough/C0 and trend of BMP / creatinine
- Measure or review blood pressure; screen for hypertension symptoms
- Reconcile nephrotoxic and CYP3A4-interacting drugs (gentamicin, amphotericin B, tacrolimus, ketoconazole, atorvastatin combinations per labeling)
- Screen for active infection (fever, dysuria, cough) and recent live-vaccine plans
- Verify patient avoids grapefruit/grapefruit juice and maintains consistent dosing schedule with meals
Contraindications (Neoral labeling)
- Hypersensitivity to cyclosporine or formulation ingredients
- Rheumatoid arthritis: abnormal renal function, uncontrolled hypertension, or malignancies
- Psoriasis: concomitant PUVA/UVB, methotrexate, other immunosuppressants, coal tar, or radiation; abnormal renal function, uncontrolled hypertension, or malignancies
Key interactions — intensify monitoring
| Interaction | Clinical concern | Nursing action |
|---|---|---|
| Nephrotoxic drugs (aminoglycosides, amphotericin, NSAIDs) | Additive renal injury | Increase creatinine/trough surveillance; hold and notify if renal function worsens |
| Strong CYP3A4 inhibitors (azole antifungals, macrolides, HIV protease inhibitors) | Higher cyclosporine exposure | Anticipate trough review after any new inhibitor starts |
| CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) | Lower exposure—rejection risk | Do not stop inducer without prescriber plan; verify levels after changes |
| Grapefruit juice | Increased blood concentration | Teach avoidance; document dietary counseling |
| Prednisone / other immunosuppressants | Increased infection and malignancy risk | Infection screen every contact; avoid live vaccines |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral modified solution (Neoral): Draw dose with provided syringe; dilute in orange or apple juice at room temperature (or water per labeling)—avoid milk because palatability may reduce intake. Take on a consistent schedule regarding meals; high-fat meals decrease absorption.
- Swallow modified capsules whole; do not open or crush unless specific product instructions allow
- Use the same juice diluent and timing pattern each day when on oral solution
- IV cyclosporine (Sandimmune) is specialist-managed—verify infusion rate and concentration per institutional policy
- Alcohol is present in Neoral formulations—consider in pregnancy, lactation, liver disease, and pediatric patients per labeling
Any pharmacy switch between modified and non-modified cyclosporine requires prescriber supervision and extra trough monitoring—never accept a 1:1 mg substitution without documented conversion plan.
Expected therapeutic response
- Transplant: stable graft function with target trough range and no rejection signs (protocol-defined)
- Rheumatoid arthritis: reduced joint swelling, pain, and morning stiffness over weeks
- Psoriasis: improved plaque thickness and body-surface involvement when renal function remains acceptable
- Lack of improvement or rising creatinine should trigger prescriber/pharmacy review—not silent dose continuation
Red flags — Stop and act
Immunosuppression plus nephrotoxicity means early escalation saves kidneys and grafts.
- Oliguria, rapid creatinine rise, or BUN/creatinine pattern suggesting toxicity vs rejection—notify transplant/renal team same day
- Supratherapeutic trough with tremor, headache, or confusion—possible neurotoxicity; hold and clarify dose
- Severe hypertension, headache, visual changes, or seizure—consider PRES per labeling; emergency evaluation
- Jaundice, dark urine, or marked transaminase rise—hepatotoxicity pathway
- Sepsis signs, opportunistic infection, or new neurologic deficits (PML concern in labeling)
- Anaphylaxis or angioedema after dose
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nephrotoxicity (creatinine/BUN rise, structural kidney injury) | Boxed warning; dose- and duration-related | Trend renal labs; dose reduction/discontinuation per protocol; differentiate from rejection with team |
| Hypertension | Common; may persist | Monitor BP; avoid potassium-sparing diuretics per labeling; notify if uncontrolled |
| Hyperkalemia / hyperuricemia | Occasional | Review BMP potassium; coordinate management with prescriber |
| Hepatotoxicity (elevated enzymes, jaundice, liver failure reports) | Labeled warning; higher early post-transplant | Monitor LFTs; stop and escalate for symptomatic hepatitis pattern |
| Neurotoxicity (tremor, paresthesia, seizure, PRES) | Labeled warning | Assess neurologic status; hold and notify for new severe symptoms |
| Infection and malignancy (including skin cancers) | Boxed warning for immunosuppression | Infection vigilance; sun protection teaching; report new masses or B symptoms |
| Gingival hyperplasia, hirsutism, gum bleeding | Common nuisance effects | Oral hygiene teaching; document for prescriber awareness |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Neoral overdosage experience is limited. Oral doses up to about 10 g have been tolerated with vomiting, drowsiness, headache, and tachycardia; serious intoxication has been reported after accidental parenteral overdose in premature neonates.
Overdose management (labeling)
- No specific antidote is listed—management is supportive and symptomatic
- Forced emesis and gastric lavage may be useful up to 2 hours after oral ingestion
- Expect possible transient hepatotoxicity and nephrotoxicity that may resolve after drug withdrawal
- Cyclosporine is not dialyzable to a great extent; charcoal hemoperfusion clearance is limited
- Contact local poison control or medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Neoral (modified) vs Sandimmune (non-modified)—similar names; verify NDC/product image before administration
- Cyclosporine vs tacrolimus—both calcineurin inhibitors with different trough targets; never interchange
- Cyclosporine vs cycloserine (tuberculosis drug)—read full drug name on MAR
- Oral solution strength—confirm mg vs mL on syringe; use only provided measuring device
- Duplicate immunosuppression—MAR may list cyclosporine plus tacrolimus after protocol change; hold and clarify
- Topical ophthalmic vs systemic—Restasis orders are not interchangeable with transplant doses
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Do not crush modified capsules unless product-specific guidance allows; use ordered formulation |
| Food timing | Take consistently with respect to meals; high-fat meals lower absorption |
| Grapefruit | Avoid grapefruit and grapefruit juice (raises concentrations) |
| Oral solution | Mix with orange or apple juice at room temperature; rinse cup; avoid milk for Neoral solution |
| Missed dose | Not specified in the reviewed prescribing information for a universal rule—follow prescriber and transplant protocol |
| Commonly missed | Assuming pharmacy substitution is equivalent; skipping trough draw before morning dose |
| Ask pharmacy when | Any formulation change, interacting drug starts, supratherapeutic trough, or pump-controlled IV rate questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Labeling advises particular renal monitoring because age-related renal decline increases toxicity risk |
| Transplant recipients on multiple immunosuppressants | Higher infection and malignancy risk; lower threshold to hold for fever or localizing infection |
| Chronic kidney disease / prior nephrotoxic exposure | May tolerate lower doses; earlier creatinine thresholds for hold |
| Psoriasis after PUVA, methotrexate, UVB, or radiation | Increased skin malignancy risk per boxed psoriasis warning |
| Pregnancy | Registry available (TPRI); increased maternal/fetal hypertension, preeclampsia, preterm birth, and low birth weight in published data—balance risks with specialist team |
| Lactation | Cyclosporine present in milk; adverse infant effects not reported in available data; consider alcohol content of Neoral and maternal clinical need |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal: serum creatinine, BUN, urine output trends (psoriasis: every 2 weeks × 3 months then monthly if stable per labeling)
- Cardiovascular: blood pressure at each visit; electrolytes including potassium and magnesium
- Hepatic: bilirubin, AST/ALT per protocol
- Immunosuppression labs: cyclosporine trough (and protocol-specific peaks) in transplant patients; periodic levels in RA when ordered
- Metabolic: lipids, uric acid as ordered
- Clinical: infection symptoms, neurologic changes (tremor, vision, confusion), graft tenderness or urine output change in transplant patients
Document
- Exact product (modified vs non-modified), dose, route, and time relative to meals
- Most recent trough result, assay type if known, and prescriber target range
- Creatinine percent change from baseline and hold/dose-change communications
- Patient teaching on grapefruit avoidance, infection reporting, and blood pressure self-monitoring when applicable
Patient teaching
- Take cyclosporine at the same times daily and the same way with regard to meals—do not change juice or food pattern without asking the team
- Avoid grapefruit and grapefruit juice; ask before any new medicine, herb, or NSAID
- Report decreased urine, swelling, severe headache, vision changes, tremor, fever, cough, or painful urination immediately
- Do not receive live vaccines during therapy unless the prescriber plans otherwise
- Use sun protection and report new or changing skin lesions—especially if prior light therapy or methotrexate was used for psoriasis
- Carry a medication list noting immunosuppression for dental, surgical, and emergency care
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to cyclosporine or formulation components
- Uncontrolled hypertension or abnormal renal function when labeled contraindicated (RA/psoriasis populations)
- Formulation/product change on MAR without documented conversion plan (modified ↔ non-modified)
- Supratherapeutic trough or rapid creatinine rise meeting institutional/transplant hold thresholds
- Psoriasis therapy: creatinine ≥25% above baseline (repeat in 2 weeks; reduce dose 25–50% if persistent) or ≥50% above baseline per labeling
- Active serious infection, suspected sepsis, or scheduled live-vaccine administration
- New nephrotoxic drug (e.g., aminoglycoside) started without updated monitoring orders
- Particulate/discolored oral solution, wrong syringe dose, or patient unable to tolerate oral intake when oral route is required
Transplant rejection vs nephrotoxicity requires specialist interpretation—holding the dose and notifying the team is appropriate when renal status acutely worsens.
Clinical practice integration and workflow
On transplant and autoimmune floors, cyclosporine safety is a systems problem: correct product, timed trough, and renal trend must align before the capsule is swallowed.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and formulation (modified vs non-modified)
- Compare trough to prescriber target and check creatinine change from baseline
- Review BP and infection screen; confirm no live vaccine due
- Oral solution: correct diluent, syringe marking, and administration time vs meals
2. High-alert and safety badge
Not on all institutional high-alert lists, but behaves as narrow-index immunosuppressionTreat cyclosporine with transplant-level rigor: independent double-check on formulation switches and trough timing.
3. Clinical workflow: hold and question rules
- If creatinine jumps ≥25% above baseline on psoriasis therapy, hold pending repeat lab and prescriber direction per labeling
- If pharmacy dispensed a different cyclosporine product, hold until conversion plan and extra levels are ordered
- If patient reports fever with graft pain or urine output drop, hold immunosuppression only per protocol but escalate immediately
4. Critical teach-back questions
- “What drinks or foods should you avoid with cyclosporine?” (Patient should mention grapefruit/grapefruit juice and maintaining consistent meal timing.)
- “What symptoms mean you should call before the next dose?” (Patient should include less urine, swelling, fever, severe headache, tremor, or yellowing skin.)
5. Care coordination
Pharmacist / transplant pharmacy: Trough interpretation, formulation conversion, interaction management
Prescriber / transplant or rheumatology team: Dose changes, rejection workup, and hold/resume decisions
🧠 Quick mental checklist
- Modified or non-modified product—does MAR match the vial label?
- Is today's trough drawn before the morning dose when ordered?
- Creatinine trend vs baseline—hold threshold met?
- Any new nephrotoxic or CYP3A4 drug since last dose?
- Fever, dysuria, cough, or neurologic changes?
Cyclosporine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for cyclosporine nephrotoxicity and trough safety using a tabbed kidney-transplant case (MAR, labs, I&O, nursing notes), then priority action, SATA cue recognition, renal trend interpretation, documentation cloze, ordered escalation steps, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Cyclosporine (Neoral) 100 mg PO BID — 0900 dose held pending trough review
- Prednisone 15 mg PO daily
- Mycophenolate mofetil 750 mg PO BID
- Gentamicin 80 mg IV q12h × 2 days (day 2 of 3) for UTI
- Pharmacy alert: yesterday's discharge med list showed Sandimmune—today's cart has Neoral capsules
- Baseline creatinine 1.1 mg/dL on admission
- Day 10: creatinine 1.2 mg/dL; cyclosporine trough 185 ng/mL (TDx assay)
- Day 14 AM: creatinine 1.6 mg/dL; BUN 38 mg/dL; K+ 5.4 mEq/L
- Day 14 trough (pre-dose): 310 ng/mL (target per protocol 150–250 ng/mL)
- AST 48 U/L, ALT 52 U/L
- Yesterday 24 h urine output: 1420 mL (previously 2100–2400 mL/day)
- Today 0600–0900: 180 mL urine; patient reports "swollen ankles"
- Oral intake fair; no vomiting
- Weight up 1.8 kg since day 10
- 0845: Fine hand tremor noted; patient alert, denies headache or visual changes
- 0850: Nurse held 0900 cyclosporine after reviewing labs and pharmacy formulation alert
- 0905: Patient asks why medication looks different ("orange capsule" vs prior "softgel")
- 0910: Transplant coordinator notified; repeat BMP and trough per protocol ordered
Answer key & rationale
Frequently asked questions
Why must nurses verify cyclosporine formulation before every dose?
Neoral (modified) and Sandimmune (non-modified) are not bioequivalent. Mg-for-mg switching without supervision can cause toxicity from higher exposure or graft risk from lower exposure.
What should I check before giving cyclosporine?
Confirm product and route, review trough and creatinine trend, blood pressure, infection symptoms, interacting drugs, and grapefruit avoidance. Draw pre-dose trough when ordered.
When should cyclosporine be held?
Hold for hypersensitivity, labeled contraindications, formulation errors, supratherapeutic trough, creatinine rises meeting protocol (including ≥25% above baseline in psoriasis), serious infection, or live vaccines—then contact prescriber/pharmacist.
Is there an antidote for cyclosporine overdose?
No specific antidote is listed. Care is supportive; gastric decontamination may help within 2 hours of oral ingestion. Contact poison control per facility protocol.
Which adverse effects matter most for nurses?
Nephrotoxicity, hypertension, hyperkalemia, hepatotoxicity, neurotoxicity (including PRES), and serious infection/malignancy risks require proactive monitoring and escalation.
Can patients breastfeed on cyclosporine?
Cyclosporine is present in human milk; no adverse infant effects are reported in available data. Weigh breastfeeding benefits against maternal need and Neoral alcohol content with the specialist team.
References
- U.S. National Library of Medicine. NEORAL (cyclosporine) capsule and oral solution — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94461af3-11f1-4670-95d4-2965b9538ae3
- U.S. Food and Drug Administration. Neoral (cyclosporine) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050715s035,050716s038lbl.pdf
- U.S. National Library of Medicine. Cyclosporine capsule (non-modified) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bfca7088-fe93-abb9-3ec3-e6f5710a69c6
- Drugs and Lactation Database (LactMed). Cyclosporine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501683/
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.